Description
LY4050784 is an experimental drug being studied by Eli Lilly and Company. It is currently in Phase 1 clinical trials for advanced or metastatic solid tumors, including colorectal cancer. These early-stage trials are primarily focused on determining the safety and tolerability of LY4050784, both when given alone and in combination with other chemotherapy drugs (like carboplatin, cisplatin, paclitaxel, pemetrexed) or immunotherapy (like pembrolizumab). The trials are also looking at whether LY4050784 shows any signs of effectiveness. Some trials are specifically looking at patients with tumors that have a specific alteration called BRG1 (also known as SMARCA4). LY4050784 is not yet approved for any use.
Mechanism of Action
LY4050784 is being investigated as a potential treatment for certain cancers. The specific way it works (its mechanism of action) is still being studied in clinical trials. Researchers are trying to understand how it affects cancer cells and whether it can shrink tumors or slow their growth.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.